<pad> Cases/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM426457.pdf.* F emales who received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, were na<unk>ve (polymerase chain reaction [PCR] negative and seronegative) to the relevant HPV type(s) before dose 1, and who remained PCR negative to the relevant HPV type(s) through 1 month after dose 3 (month 7). Because the additional five types in 9vHPV account for a higher proportion of HPV-associated cancers in females compared with males and cause cervical precancers, the additional protection from 9vHPV will mostly benefit females.Recommendations for Use of HPV VaccinesACIP recommends that routine HPV vaccination be initi -ated at age 11 or 12 years.</s>